A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML
Pediatric AML is traditionally treated with chemotherapy and stem cell transplant but some subsets of patients have a poor response to therapy. Here, the authors perform a high throughput screen and identify several FDA approved drugs that might be useful in treating this disease.
Guardado en:
Autores principales: | Christina D. Drenberg, Anang Shelat, Jinjun Dang, Anitria Cotton, Shelley J. Orwick, Mengyu Li, Jae Yoon Jeon, Qiang Fu, Daelynn R. Buelow, Marissa Pioso, Shuiying Hu, Hiroto Inaba, Raul C. Ribeiro, Jeffrey E. Rubnitz, Tanja A. Gruber, R. Kiplin Guy, Sharyn D. Baker |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f909cbdab341455d9f702b6081a46e6f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
TARGETED THERAPY IN AML TREATMENT
por: Giovanni Martinelli
Publicado: (2021) - JAK-STAT
-
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
por: Panagiotis A. Konstantinopoulos, et al.
Publicado: (2021) -
Jak nas widzą…
por: Zuzanna Łopacińska‑Piędel
Publicado: (2021) -
Jak badać politykę?
por: Marek Pająk
Publicado: (2014)